1235 / 1816
PRE-CLINICAL STUDIES OF THE THERAPEUTIC EFFECT OF A
PARP INHIBITOR COMBINED WITH RADIOTHERAPY FOR BREAST
CANCER TREATMENT,
Pouzoulet et al, AACR 2013
Our preclinical results confirm the susceptibility of TNBC to ionizing radiation and the
impact of
BRCA2
mutations on this sensitivity. Such a characterization of highly relevant
preclinical models supports their use for pharmacological assessments that will combine both
radiotherapy and new therapeutic approaches to improve the outcome of TNBC patients